Rifaximin complexes

Abstract

There is provided a complex comprising rifaximin and a complexing agent, wherein the complexing agent is a polyvinyl pyrrolidone (PVP) or a cyclodextrin. There is also provided a process for preparing the complex, a pharmaceutical composition including the complex and therapeutic uses of the complex.

1 - 24 . (canceled) 
     
     
         25 . A method of treating bowel disorders comprising:
 administering to a patient a therapeutically effective amount of a complex comprising rifaximin and a complexing agent, wherein the complex is in an amorphous form and exhibits enhanced solubility compared to a physical mixture of rifaximin and the complexing agent.   
     
     
         26 . The method of  claim 25 , wherein the complex is a component of a tablet, a pellet, or a capsule. 
     
     
         27 . The method of  claim 25 , wherein the bowel disorder is travelers' diarrhea. 
     
     
         28 . The method of  claim 25 , wherein the bowel disorder is a bowel disease. 
     
     
         29 . The method of  claim 25 , wherein the bowel disorder is irritable bowel syndrome, Crohn's disease, chronic pancreatitis, pancreatic insufficiency and/or colitis. 
     
     
         30 . The method of  claim 25 , wherein the bowel disorder is microbe associated diarrhea. 
     
     
         31 . The method according to  claim 25 , wherein the ratio of rifaximin to complexing agent ranges from 20:1 to 1:20 w/w. 
     
     
         32 . The method according to  claim 25 , wherein the ratio of rifaximin to complexing agent ranges from 10:1 w/w to 1:2 w/w. 
     
     
         33 . The method according to  claim 25 , wherein the rifaximin complex is administered with one or more pharmaceutically acceptable excipients.